Prevest Denpro Ltd (PREVEST)

Loading page…

Prevest Denpro Ltd (PREVEST) · mywealthgrid

About

Prevest Denpro manufactures medical equipment and supplies in India, operating at ₹461 Cr market cap with recent quarterly revenue of ₹18.54 Cr. The company maintains strong profitability (35% OPM, 18.7% ROE, zero debt) and pays regular dividends, but the stock has fallen 28% over the past year.

Face value: ₹10

Market cap

₹452 Cr

P/E

22.1×

P/B

—

Dividend yield

0.3%

ROE

—

ROCE

—

Debt / equity

—

OPM

34.4%

EPS (TTM)

₹17.1

Book value

—

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin compressed 600bp from 41.36% (Dec 2021) to 35.7% (Mar 2025)—verify if cost or pricing pressures are structural
Stock down 28% in 1 year despite profitability and dividends—verify if valuation reset, sector headwinds, or liquidity constraints explain the divergence
PE of 25.39 prices in growth; verify if historical 66% revenue growth (₹11.12 Cr to ₹18.54 Cr over 3+ years) can sustain
Public float ~25%, promoter 74%—verify impact on trading liquidity and institutional participation

Generated analysis · source review pending

Growth drivers

Revenue grew 66% from ₹11.12 Cr (Dec 2021) to ₹18.54 Cr (Mar 2025); verify if momentum continues
Net profit expanded 40% (₹3.75–₹5.25 Cr) over same period; verify if absolute growth sustains amid 600bp margin compression
D/E of 0 provides capital flexibility; verify strategy for capex, R&D, or M&A deployment
Dividends in 2024–2025 show cash generation; verify if capital prioritizes reinvestment or shareholder distribution

Generated analysis · source review pending

1,231 historical price candles were omitted because the exchange source has not been verified.

₹377.1-2.1%1Y

Quick read

rule-based

Pros

+Strong return on equity of 18.5% (3-yr avg)
+High return on capital employed of 24.4%
+Healthy operating margin of 34.4%
+High promoter holding of 73.6% with no pledge

Cons

−Low dividend payout of 5.9% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

77/100

Business quality: 98
Valuation: 56

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Molbio Diagnostics LimitedMOLBIOMOLBIO	₹17,431 Cr	₹17,844 Cr	₹1,020 Cr	₹262 Cr	25.7%	₹145 Cr	13.6%	23.7%	16.2%	—
Poly Medicure LimitedPOLYMEDPOLYMED	₹16,610 Cr	₹16,952 Cr	₹1,997 Cr	₹461 Cr	23.6%	₹315 Cr	17.1%	14.5%	11%	294
Fischer Medical Ventures LimitedFISCHERFISCHER	₹2,190 Cr	₹2,262 Cr	₹367 Cr	₹50 Cr	14%	₹30 Cr	10.1%	13.6%	8.6%	111
Tarsons Products LimitedTARSONSTARSONS	₹1,752 Cr	₹2,135 Cr	₹441 Cr	₹119 Cr	27.9%	₹11 Cr	3.4%	5%	2.3%	361
Laxmi Dental LimitedLAXMIDENTLLAXMIDENTL	₹1,066 Cr	₹1,066 Cr	₹287 Cr	₹46 Cr	15.6%	₹31 Cr	10.4%	14.7%	12.8%	109
Hemant Surgical Industries LtdHSILHSIL	₹885 Cr	—	₹232 Cr	₹23 Cr	10%	₹18 Cr	7.9%	—	—	—
Fabtech Technologies LimitedFABTECHFABTECH	₹632 Cr	₹675 Cr	₹418 Cr	₹45 Cr	8.5%	₹49 Cr	9.3%	15.5%	12.9%	55
Prevest Denpro LtdPREVESTPREVEST	₹452 Cr	—	₹72 Cr	₹25 Cr	34.4%	₹20 Cr	28.5%	—	—	—
Nureca LimitedNURECANURECA	₹332 Cr	₹333 Cr	₹153 Cr	₹4 Cr	0.1%	₹4 Cr	1.4%	3.3%	1.1%	186
Earkart LtdEARKARTEARKART	₹179 Cr	₹179 Cr	₹54 Cr	₹8 Cr	15.5%	₹5 Cr	9.1%	12.1%	7.7%	243
Choksi Asia LtdCHOKSICHOKSI	₹117 Cr	₹119 Cr	₹11 Cr	₹-2 Cr	13.8%	₹2 Cr	10.8%	18.9%	13.5%	142
Shree Pacetronix LtdSHREEPACSHREEPAC	₹68 Cr	₹71 Cr	₹8 Cr	₹1 Cr	23.5%	₹0 Cr	14%	27.4%	18.9%	385

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	56	63	72
COGS	14	12	17
Gross profit	43	51	55
	23	29	30
	20	22	25
OPM %	35.2%	35.1%	34.4%
Depreciation	1	2	2
Interest	0	0	0
	3	4	5
Profit before tax	21	24	28
Tax	5	6	7
Tax %	24.7%	25.1%	25.8%
	16	18	20
PAT margin %	28.6%	28.8%	28.5%
EPS (₹)	13.5	15.1	17.1
EPS adjusted (₹)	13.5	15.1	—
	7.4%	6.6%	5.9%
Annual report	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2024	Mar 2025	Mar 2026
Equity capital	12	12	—
Reserves	77	94	—
	0	0	—
	6	7	133
Total equity & liabilities	95	113	133
	27	27	27
CWIP	0	0	—
Investments	2	5	9
	66	81	98
Total assets	95	113	133

₹ Cr	Mar 2024	Mar 2025	Mar 2026
	12	15	15
	-2	-1	-2
	-0	-1	-1
Net cash flow	10	12	12
Free cash flow	8	15	13
CFO / Operating profit %	58.5%	67.1%	59.9%

Compounded sales growth

7 years: —
5 years: —
3 years: —
1 year: 14%

Compounded profit growth

7 years: —
5 years: —
3 years: —
1 year: 13%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: 17%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	76%	80.6%	76.9%
EBITDA margin %	35.2%	35.1%	34.4%
EBIT margin %	32.9%	32%	31.6%
PAT margin %	28.6%	28.8%	28.5%
Working capital
Receivable days	53	44	—
Inventory days	168	240	239
Payable days	16	32	—
NWC days	205	251	—
Leverage
Current ratio	12.35	14.38	14.91
Debt to EBITDA	0	0	—
Debt to equity	0	0	—
Interest coverage	—	—	—
Asset turnover	0.6	0.56	0.54
Return ratios
Return on assets %	17%	16.1%	15.4%
Return on capital employed %	24%	24.8%	23.7%
Return on equity %	18.2%	17.2%	—

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	73.6%	73.6%	73.6%	73.6%	73.6%	73.6%	73.6%	73.6%
	0.63%	0.63%	0.63%	0.63%	0.63%	0.65%	0.65%	0.65%
	0.68%	0.71%	1.28%	1.22%	0.75%	0.77%	0.77%	0.79%
Government	0%	0%	0%	0%	0%	0%	0%	0%
	25.09%	25.06%	24.49%	24.55%	25.02%	24.98%	24.98%	24.96%
No. of shareholders	1,822	1,832	1,887	1,928	1,888	1,957	1,960	1,975

Promoter holding up 0 percentage points since Sep 2024.

Atul ModiChairman & Managing Director
Namrata ModiWhole Time Director & CFO
Dr. Sai Kalyan SurapaneniDirector
Niharika ModiNon-Executive Director
Mr. Abhijeet Sadashiv HaridasNon - Executive Independent Director
Mr. Piyush Kiranprakash GuptaNon - Executive Independent Director
Mr. Sukhen Pal BabutaNon - Executive Non -Independent Director
Mr. Pratul GuptaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Prevest Denpro Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

3

Final dividend4 Sept 2026 · ex-date₹1
Final dividend3 Sept 2025 · ex-date₹1
Final dividend30 Aug 2024 · ex-date₹1

1

Board meeting to consider results11 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

12 announcementsExport CSV

28 Sept 2026, 3:17 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

19 Sept 2026, 6:29 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

AGM PDF

17 Sept 2026, 5:57 pmAGM/EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

AGM PDF

21 Aug 2026, 3:33 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

20 Aug 2026, 5:41 pmCompany Update

The Company Has Sent Letter To The Shareholder For AGM Whose Email Id Was Not Registered With RTA.

General PDF

20 Aug 2026, 2:50 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

20 Aug 2026, 1:37 pmAGM/EGM

Notice Of The 27Th Annual General Meeting ('AGM') Of The Company To Be Held On Thursday, September 17, 2026, At 12:30 P.M.

AGM PDF

19 Aug 2026, 3:10 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
28 Sept 2026, 3:17 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
19 Sept 2026, 6:29 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF

Loading announcements…

Prevest Denpro Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Dividends3

Board meetings1

Announcements

Ratio timeline

Quarterly record

Board and management

Not in the F&O segment

Dividends3

Board meetings1

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

1

3

1